Table 3.

¹²⁴I-PU-H71 accumulates in tumors, with negligible retention in most normal organs.

Organ	4 hour (n=30)		24 hour (n=30)
	Mean SUV	Mean SD	Mean SUV	Mean SD
Aortic blood pool	0.5	0.2	0.2	0.1
Appendicular skeleton* (humerus)*	0.5	0.3	0.3	0.3
Axial skeleton*	1.0	0.3	0.3	0.3
Brain	0.1	0.1	0.1	0.2
Kidney	1.5	0.6	0.6	0.4
Liver	6.4	2.3	2.3	1.7
Lung	0.4	0.2	0.2	0.1
Muscle, skeletal	0.4	0.2	0.2	0.1
Myocardium	2.8	1.0	1.7	1.1
Spleen	2.0	1.2	0.7	0.4
Thyroid	2.3	1.3	1.1	0.9
Tumors	1.9	2.0	0.9	0.8

Note: Biodistribution and tumor uptake at 4 and 24 hours after tracer injection. Shown are study population (n=30 patients) average and standard deviation values for tracer uptake in major organs and tracer-avid tumors in terms of standardized uptake value (SUV average; see Methods). Thyroid uptake likely represents free radioiodide uptake (product of in vivo tracer metabolism); hepatic uptake likely represents tracer metabolism and hepatobiliary excretion.

^*Tracer uptake in humerus considered representative of compact bone/osteogenic cell tracer avidity and the spine representative of tracer uptake in bone red marrow (see Results).